Complete remission with imatinib in metastastic gastrointestinal stromal tumors [7]

Journal of Clinical Oncology

Volumn 23, Issue 27, 2005, Pages 6800-6801

  Bauer, Sebastian ^a   Lang, Hauke ^a   Schütte, Jochen ^a   Hartmann, Jörg Thomas ^a  

^a UNIVERSITY OF ESSEN MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; STEM CELL FACTOR RECEPTOR; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

CANCER PATIENT; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; FALSE NEGATIVE RESULT; GASTROINTESTINAL STROMAL TUMOR; HUMAN; LETTER; LONG TERM CARE; METASTASIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TREATMENT RESPONSE; CANCER STAGING; CASE REPORT; FOLLOW UP; LIVER TUMOR; NOTE; PATHOLOGY; TREATMENT OUTCOME;

FOLLOW-UP STUDIES; GASTROINTESTINAL STROMAL TUMORS; HUMANS; LIVER NEOPLASMS; NEOPLASM METASTASIS; NEOPLASM STAGING; PIPERAZINES; PYRIMIDINES; TREATMENT OUTCOME;

EID: 27244451636     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.02.1063     Document Type: Letter

References (7)

1. Chacon M, Roca E, Huertas E, et al: CASE 3. Pathologic complete remission of metastatic gastrointestinal stromal tumor after imatinib mesylate. J Clin Oncol 23:1580-1582, 2005
2. Scaife CL, Hunt KK, Patel SR, et al: Is there a role for surgery in patients with "unresectable" cKIT+ gastrointestinal stromal tumors treated with imatinib mesylate? Am J Surg 186:665-669, 2003
3. Bauer S, Hartmann JT, Lang H, et al: Imatinib may enable complete resection in previously unresectable or metastatic GIST. J Clin Oncol, 2004 (abstr 9023)
4. Bauer S, Hartmann JT, Lang H, et al: Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib. Int J Cancer 117:316-325, 2005
5. Putnam JB Jr., Roth JA: Surgical treatment for pulmonary metastases from sarcoma. Hematol Oncol Clin North Am 9:869-887, 1995
6. Wiklund T, Saeter G, Strander H, et al: The outcome of advanced soft tissue sarcoma patients with complete tumour regression after either chemotherapy alone or chemotherapy plus surgery. The Scandinavian Sarcoma Group experience. Eur J Cancer 33:357-361, 1997
7. Blay JY, Berth, Berthaud P, et al: Continuous vs intermittent imatinib treatment in advanced GIST after one year: A prospective randomized phase III trial of the French Sarcoma Group. J Clin Oncol, 2004 (abstr 9006)